Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer
Completed · Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Paclitaxel may stop the growth of breast cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to compare the effectiveness of paclitaxel with or without trastuzumab following peripheral stem cell transplantation in treating patients who have refractory stage IV breast cancer.
Key facts
- Study ID
- NCT00004013
- Run by
- Fred Hutchinson Cancer Center
- People needed
- 60
- Starts
- 1999-01-01
- Expected to finish
- 2001-10-01
- Last updated by the study team
- 2010-04-02
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.